Race Oncology Ltd Sustainability Reports
A clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, specifically advancing a proprietary formulation of bisantrene to address high unmet needs in oncology and provide cardioprotection.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 9845004A1AE3E97Q1296
FIGI: BBG00CWVFMT3
8 reports from 2016 to 2025